EHA 2022 | Phase II study of epcoritamab in R/R LBCL
Catherine Thieblemont, MD, PhD, Saint-Louis University Hospital, Paris, France, gives an overview of the results of a Phase II study evaluating subcutaneous epcoritamab dose expansion in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (NCT03625037). The study reported impressive efficacy and mild toxicity. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research Funding: Hospira, Roche, Bristol Myers Squibb/Celgene; Consultancy: AbbVie, Cellectis, Amgen, Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences; Honoraria: AbbVie, Bayer, Cellectis, Amgen, Incyte, Kite, Takeda, Janssen, Novartis, Gilead Sciences; Membership on an entity’s Board of Directors or advisory committees: AbbVie, Cellectis, Amgen, Incyte, Kite, Takeda, Janssen, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences; Other: Travel, Accommodations, Expenses: AbbVie, Cellectis, Amgen, Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, Gilead Sciences
